-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals
Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues . Processed and ... mehr